Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.
Change log
Authors
Abstract
Apelin and its G protein-coupled receptor (GPCR) have emerged as a key signalling pathway in the cardiovascular system. The peptide is a potent inotropic agent and vasodilator. Remarkably, a peptide, Elabela/Toddler, that has little sequence similarity to apelin, has been proposed as a second endogenous apelin receptor ligand and is encoded by a gene from a region of the genome previously classified as 'non-coding'. Apelin is downregulated in pulmonary arterial hypertension and heart failure. To replace the missing endogenous peptide, 'biased' apelin agonists have been designed that preferentially activate G protein pathways, resulting in reduced β-arrestin recruitment and receptor internalisation, with the additional benefit of attenuating detrimental β-arrestin signalling. Proof-of-concept studies support the clinical potential for apelin receptor biased agonists.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1873-3735
Volume Title
Publisher
Publisher DOI
Sponsorship
British Heart Foundation (None)
Medical Research Council (MC_PC_12012)
Wellcome Trust (085686/Z/08/J)